AU Patent

AU2020293622A1 — [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough

Assigned to Axalbion SA · Expires 2022-02-03 · 4y expired

What this patent protects

The present invention pertains generally to the field of therapy. More specifically the present invention pertains to a certain compound, [((1R,2S,5R)-2-isopropyl-5-methyl- cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester (also referred to herein as "AX-8" or "…

USPTO Abstract

The present invention pertains generally to the field of therapy. More specifically the present invention pertains to a certain compound, [((1R,2S,5R)-2-isopropyl-5-methyl- cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester (also referred to herein as "AX-8" or "Gly-O-iPr"), as described herein, for use in a method of treatment of the human or animal body by therapy, more specifically, for use in a method of treatment of chronic cough (CC), including, for example, refractory chronic cough (RCC) and idiopathic chronic cough (ICC), as described herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020293622A1
Jurisdiction
AU
Classification
—
Expires
2022-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Axalbion SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.